Carbocysteine

Summary

Carbocysteine (CHEMBL396416) is a phase-3 clinical-stage small-molecule mucolytic (ATC R05CB03); indicated across 1 condition including bronchiectasis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: R05CB03
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 179.2 Da · C5H9NO4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL396416
Name	Carbocysteine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	193653
ChEBI	CHEBI:16163
ATC	R05CB03
Molecular formula	C5H9NO4S
Molecular weight	179.2
InChIKey	GBFLZEXEOZUWRN-VKHMYHEASA-N

SMILES: C([C@@H](C(=O)O)N)SCC(=O)O

IUPAC name: (2R)-2-amino-3-(carboxymethylsulfanyl)propanoic acid

ChEBI definition: An L-cysteine thioether that is L-cysteine in which the hydrogen of the thiol group has been replaced by a carboxymethyl group.

Pharmacological roles (ChEBI): mucolytic.

Also known as: AHR-3053, Carbocistein, Carbocisteina, Carbocisteine, Carbocit, Carbocysteine, Carbocysteine dl-form, dl-, L-carbocisteine, L-carbocysteine, Lisomucil, LJ 206

Parent form; salt/anhydrous children: CHEMBL4303635

Patent coverage: 2,036 distinct patent families (6,521 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
bronchiectasis	3	MONDO:0004822	HP:0002110

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04140214	PHASE3	COMPLETED	Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis (CLEAR)
NCT06863376	PHASE2	RECRUITING	Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
NCT02015598	Not specified	COMPLETED	Antioxidant Carbocysteine Treatment in Obstructive Sleep Apnoea Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 8 clinical and 8 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).